Pantothenic Acid

Summary

Pantothenic Acid (CHEMBL1594) is an approved small-molecule geroprotector; indicated across 2 conditions including chronic kidney disease and heart failure.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Indications: 2 conditions
• Clinical trials: 1
• Chemistry: 219.23 Da · C9H17NO5

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1594
Name	Pantothenic Acid
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	6613
ChEBI	CHEBI:46905
Molecular formula	C9H17NO5
Molecular weight	219.23
InChIKey	GHOKWGTUZJEAQD-ZETCQYMHSA-N

SMILES: CC(C)(CO)[C@H](C(=O)NCCC(=O)O)O

IUPAC name: 3-[[(2R)-2,4-dihydroxy-3,3-dimethylbutanoyl]amino]propanoic acid

ChEBI definition: A pantothenic acid having R-configuration.

Pharmacological roles (ChEBI): antidote to curare poisoning, geroprotector.

Other ChEBI roles (chemical / environmental): human blood serum metabolite.

Also known as: Calc pantoth, Cantopal, Chick antidermatitis factor, Pantothenate, Pantothenic acid, Pantothenic acid (d), Pantothenic acid component of vitaped, Vitamin b-5, Vitamin b5, Vitamin b 5, PANTOTHENIC ACID, Vitamin B5

Parent form; salt/anhydrous children: CHEMBL1901349

Patent coverage: 57,557 distinct patent families (144,026 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
chronic kidney disease	4	MONDO:0005300	EFO:0003884
heart failure	2	MONDO:0005252	EFO:0003144

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05701501	Not specified	UNKNOWN	Clinical Study of Vitamin B5 in Adjuvant Treatment of IBD

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).